Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting

Bone Marrow Transplantation volume 44, pages 237–242 (2009)Cite this article

Abstract

SCT from an HLA-compatible sibling donor is an adoptive immunotherapy for cytokine-refractory, metastatic clear-cell renal cell cancer (RCC). However, the recent introduction of targeted therapy compounds has reduced the interest in this therapeutic strategy. We have reanalyzed our series with the aim to assess long-term benefit from allografting. Twenty-five RCC patients received a reduced-intensity allograft from an HLA-identical sibling donor. All patients received a thiotepa, fludarabine and CY conditioning regimen, and a cyclosporine-based GVHD prophylaxis. Best response to allograft was evaluable in 24 patients: 1 CR, 4 PR, 12 minor response/stable disease, 7 progressive disease. One-year survival was 48%, and five-year survival was 20%. At a median observation time of 65 months, five patients are alive, one in CR, one in PR and three with stable disease. By multivariate analysis, C-reactive protein value before transplant, the number of CD34+ infused cells and disease status at day +90 significantly correlated with survival. Survival of patients at favorable/intermediate-risk according to the MSKCC score that underwent allografting was better in comparison to the survival predicted by historical controls. We conclude that 20% of cytokine-refractory RCC patients are alive long-term after allografting. Transplantation is able to induce long-term disease control in a fraction of relapsed RCC patients

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750–758.

    Article  CAS  Google Scholar 

  2. Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol 2008; 5: 256–267.

    Article  CAS  Google Scholar 

  3. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006; 17: 1134–1140.

    Article  CAS  Google Scholar 

  4. Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F et al. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 2005; 104: 2099–2103.

    Article  Google Scholar 

  5. Motzer RJ, Bukowski RM . Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 5601–5608.

    Article  CAS  Google Scholar 

  6. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234–4236.

    Article  CAS  Google Scholar 

  7. Cox DR . Regression models and life tables. J R Stat Soc 1972; 34 Series B: 187.220–226.

  8. Klein JP, Rizzo JD, Zhang MJ, Keiding N . Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis. Bone Marrow Transplant 2001; 28: 909–915. Part II: Regression modelling. Bone Marrow Transplant 2001; 28: 1001–1011.

    Article  CAS  Google Scholar 

  9. Kaplan EL, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  10. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993–2003.

    Article  Google Scholar 

  11. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454–463.

    Article  Google Scholar 

  12. Takahashi Y, Harashima N, Kajigaya SH, Yokoyama H, Cherkasova E, McCoy JP et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest 2008; 118: 1099–1109.

    Article  CAS  Google Scholar 

  13. Blaise D, Bay JO, Faucher C, Michallet M, Boiron JM, Choufi B et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435–441.

    Article  CAS  Google Scholar 

  14. Hudes G, Carducci M, Tomczac P, Dutcher J, Figlin R, Kapoor A et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271–2281.

    Article  CAS  Google Scholar 

  15. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103–2111.

    Article  Google Scholar 

  16. Motzer RJ, Hutson TE, Tomczac P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–124.

    Article  CAS  Google Scholar 

  17. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125–134.

    Article  CAS  Google Scholar 

  18. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–1103.

    Article  CAS  Google Scholar 

  19. Suppiah R, Finke J, Rini BI, Richmond A, Wood L, Elson P et al. T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during Sunitinib treatment: correlation with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias. J Clin Oncol 2006; 24: 1065a.

    Google Scholar 

  20. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111: 453–462.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the doctors and the nurses of the Bone Marrow Transplant Unit for their dedicated patient care, and Ms Stefania Trinca for data management. This work has been supported by AIRC Regional Grant and by Ricerca Finalizzata 2005 to MBr.

Author information

Authors and Affiliations

  1. Department of Oncology, Strategic Program in Oncology and Hematology Unit, Scientific Institute San Raffaele, Milan, Italy

    M Bregni, M Bernardi, P Servida, A Pescarollo, R Crocchiolo, E Treppiedi, P Corradini, F Ciceri & J Peccatori

  2. Oncology Unit, Ospedale San Giuseppe, Milano, Italy

    M Bregni

  3. Istituto Oncologico Svizzera Italiana (IOSI), Bellinzona CH, Switzerland

    P Servida

  4. Ospedale Evangelico, Genova, Italy

    A Pescarollo

  5. Istituto Nazionale Tumori, Milano, Italy

    P Corradini

Authors
  1. M Bregni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Bernardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Servida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Pescarollo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Crocchiolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Treppiedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Corradini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Ciceri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Peccatori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Bregni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bregni, M., Bernardi, M., Servida, P. et al. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplant 44, 237–242 (2009). https://doi.org/10.1038/bmt.2009.9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.9

Keywords

This article is cited by

Search

Advanced search

Quick links